Share Price and Basic Stock Data
Last Updated: January 2, 2026, 7:49 pm
| PEG Ratio | 4.28 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Lincoln Pharmaceuticals Ltd operates within the pharmaceuticals industry and has shown a steady growth trajectory in its revenue streams. The company’s sales reported for the fiscal year ending March 2025 stood at ₹623 Cr, up from ₹581 Cr in March 2024, and ₹510 Cr in March 2023. The quarterly sales figures reveal a consistent upward trend, with the latest reported sales of ₹168 Cr for the quarter ending March 2025. This demonstrates a robust growth pattern as sales increased from ₹142 Cr in the preceding quarter. The operating profit margin (OPM) has fluctuated between 15% and 20% over the last few quarters, with an OPM of 16% recorded for March 2025. Overall, Lincoln’s revenue growth aligns well with industry growth, reflecting its strong market positioning and operational efficiency.
Profitability and Efficiency Metrics
Lincoln Pharmaceuticals has maintained healthy profitability metrics, as evidenced by a reported net profit of ₹82 Cr for the fiscal year ending March 2025, slightly down from ₹93 Cr in March 2024. The net profit margin stood at 13.21% for the same period, showcasing effective cost management despite the dip in absolute profit. The company’s return on equity (ROE) was reported at 12.25%, while return on capital employed (ROCE) stood at 16.07%, indicating efficient use of shareholder funds and capital. The interest coverage ratio was exceptionally high at 65.84x, reflecting no debt on the books and strong capacity to cover interest obligations. These profitability and efficiency metrics position Lincoln favorably against industry peers, where typical ROE and ROCE can range from 12% to 18%.
Balance Sheet Strength and Financial Ratios
Lincoln Pharmaceuticals exhibits a strong balance sheet, highlighted by total reserves of ₹696 Cr and no reported borrowings, which underscores a debt-free operational model. The current ratio stood at a robust 4.71, indicating excellent liquidity to cover short-term obligations. Additionally, the company’s book value per share increased to ₹335.34 in March 2025, up from ₹295.98 in March 2024, reflecting ongoing retention of earnings. The price-to-book value ratio was reported at 1.64x, suggesting the market values the company’s equity slightly above its book value, which is typical for a growing pharmaceutical firm. The cash conversion cycle was reported at 90 days, indicating efficient management of working capital, although it is important to monitor this metric against industry standards.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Lincoln Pharmaceuticals reveals a strong promoter presence, holding 49.78% of the equity, which instills confidence among investors regarding stable management. The foreign institutional investors (FIIs) have gradually increased their stake to 4.73%, while domestic institutional investors (DIIs) remain minimal at 0.01%. The total number of shareholders has risen to 32,370, indicating growing retail interest. Notably, the promoter holding has remained stable over recent quarters, ranging from 46.34% in December 2022 to 49.78% in June 2025. The public holding decreased from 52.22% in December 2022 to 45.49% in September 2025, reflecting a shift in ownership dynamics that may influence market sentiment positively, particularly among institutional investors.
Outlook, Risks, and Final Insight
Looking ahead, Lincoln Pharmaceuticals is well-positioned for growth, supported by its strong financial metrics and a stable operational model. However, potential risks include the volatility in raw material costs and regulatory challenges inherent in the pharmaceutical industry, which could impact profit margins. Furthermore, the company’s reliance on domestic markets poses risks related to local economic fluctuations. Should Lincoln successfully navigate these challenges and continue to innovate, it could enhance its market share and profitability. Conversely, failure to adapt to market changes or regulatory shifts could hinder performance. The company’s ability to maintain its debt-free status while scaling operations will be critical in sustaining investor confidence and achieving long-term growth.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 133 Cr. | 106 | 217/84.3 | 29.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,749 Cr. | 435 | 479/192 | 98.3 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.3 Cr. | 47.6 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 53.6 Cr. | 36.6 | 37.0/17.0 | 128 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,252.22 Cr | 1,149.28 | 54.07 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 123 | 141 | 134 | 112 | 136 | 156 | 146 | 142 | 147 | 161 | 147 | 168 | 154 |
| Expenses | 107 | 112 | 107 | 96 | 115 | 125 | 117 | 124 | 125 | 133 | 123 | 141 | 130 |
| Operating Profit | 17 | 29 | 27 | 17 | 21 | 31 | 30 | 18 | 23 | 28 | 24 | 27 | 24 |
| OPM % | 14% | 21% | 20% | 15% | 15% | 20% | 20% | 13% | 15% | 18% | 16% | 16% | 15% |
| Other Income | 6 | 6 | 6 | 4 | 8 | 9 | 11 | 7 | 10 | 10 | 9 | -7 | 15 |
| Interest | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Profit before tax | 21 | 32 | 31 | 17 | 25 | 37 | 38 | 22 | 29 | 35 | 29 | 16 | 35 |
| Tax % | 28% | 26% | 29% | 26% | 25% | 25% | 26% | 16% | 20% | 24% | 28% | 29% | 22% |
| Net Profit | 15 | 24 | 22 | 13 | 19 | 28 | 28 | 19 | 24 | 26 | 21 | 12 | 28 |
| EPS in Rs | 7.49 | 11.84 | 10.79 | 6.27 | 9.49 | 13.80 | 14.00 | 9.29 | 11.82 | 13.15 | 10.37 | 5.78 | 13.82 |
Last Updated: August 20, 2025, 7:40 am
Below is a detailed analysis of the quarterly data for Lincoln Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 154.00 Cr.. The value appears to be declining and may need further review. It has decreased from 168.00 Cr. (Mar 2025) to 154.00 Cr., marking a decrease of 14.00 Cr..
- For Expenses, as of Jun 2025, the value is 130.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 141.00 Cr. (Mar 2025) to 130.00 Cr., marking a decrease of 11.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 24.00 Cr.. The value appears to be declining and may need further review. It has decreased from 27.00 Cr. (Mar 2025) to 24.00 Cr., marking a decrease of 3.00 Cr..
- For OPM %, as of Jun 2025, the value is 15.00%. The value appears to be declining and may need further review. It has decreased from 16.00% (Mar 2025) to 15.00%, marking a decrease of 1.00%.
- For Other Income, as of Jun 2025, the value is 15.00 Cr.. The value appears strong and on an upward trend. It has increased from -7.00 Cr. (Mar 2025) to 15.00 Cr., marking an increase of 22.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 35.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Mar 2025) to 35.00 Cr., marking an increase of 19.00 Cr..
- For Tax %, as of Jun 2025, the value is 22.00%. The value appears to be improving (decreasing) as expected. It has decreased from 29.00% (Mar 2025) to 22.00%, marking a decrease of 7.00%.
- For Net Profit, as of Jun 2025, the value is 28.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Mar 2025) to 28.00 Cr., marking an increase of 16.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 13.82. The value appears strong and on an upward trend. It has increased from 5.78 (Mar 2025) to 13.82, marking an increase of 8.04.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:03 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 210 | 266 | 400 | 360 | 361 | 366 | 386 | 424 | 472 | 510 | 581 | 623 | 632 |
| Expenses | 190 | 240 | 359 | 313 | 308 | 299 | 321 | 337 | 376 | 421 | 480 | 522 | 533 |
| Operating Profit | 20 | 26 | 41 | 47 | 53 | 68 | 66 | 87 | 96 | 90 | 100 | 102 | 100 |
| OPM % | 10% | 10% | 10% | 13% | 15% | 18% | 17% | 21% | 20% | 18% | 17% | 16% | 16% |
| Other Income | 2 | 7 | 7 | 2 | 5 | 5 | 11 | 5 | 10 | 22 | 34 | 22 | 25 |
| Interest | 7 | 8 | 10 | 7 | 5 | 4 | 2 | 2 | 1 | 2 | 1 | 2 | 2 |
| Depreciation | 4 | 5 | 5 | 6 | 6 | 7 | 7 | 8 | 8 | 9 | 11 | 13 | 14 |
| Profit before tax | 12 | 20 | 33 | 37 | 46 | 62 | 67 | 84 | 96 | 100 | 122 | 109 | 109 |
| Tax % | 16% | 24% | 28% | 25% | 25% | 22% | 23% | 26% | 28% | 27% | 24% | 25% | |
| Net Profit | 10 | 15 | 24 | 28 | 35 | 49 | 51 | 62 | 69 | 73 | 93 | 82 | 80 |
| EPS in Rs | 6.53 | 9.20 | 14.52 | 14.06 | 17.31 | 24.36 | 25.72 | 31.12 | 34.63 | 36.40 | 46.58 | 41.11 | 39.95 |
| Dividend Payout % | 9% | 11% | 7% | 9% | 9% | 6% | 6% | 5% | 4% | 4% | 4% | 4% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 50.00% | 60.00% | 16.67% | 25.00% | 40.00% | 4.08% | 21.57% | 11.29% | 5.80% | 27.40% | -11.83% |
| Change in YoY Net Profit Growth (%) | 0.00% | 10.00% | -43.33% | 8.33% | 15.00% | -35.92% | 17.49% | -10.28% | -5.49% | 21.60% | -39.23% |
Lincoln Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 10% |
| 3 Years: | 10% |
| TTM: | 6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 10% |
| 3 Years: | 6% |
| TTM: | -12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 18% |
| 3 Years: | 25% |
| 1 Year: | -29% |
| Return on Equity | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 16% |
| 3 Years: | 15% |
| Last Year: | 13% |
Last Updated: September 5, 2025, 9:50 am
Balance Sheet
Last Updated: December 10, 2025, 3:00 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
| Reserves | 82 | 95 | 124 | 172 | 204 | 249 | 293 | 346 | 413 | 482 | 573 | 652 | 696 |
| Borrowings | 68 | 76 | 78 | 64 | 61 | 34 | 5 | 1 | 2 | 2 | 1 | -0 | 0 |
| Other Liabilities | 93 | 70 | 56 | 48 | 62 | 63 | 71 | 85 | 99 | 83 | 106 | 125 | 139 |
| Total Liabilities | 260 | 258 | 275 | 305 | 347 | 366 | 389 | 452 | 534 | 587 | 700 | 797 | 855 |
| Fixed Assets | 65 | 66 | 98 | 103 | 117 | 121 | 123 | 111 | 132 | 151 | 179 | 182 | 185 |
| CWIP | 2 | 3 | 3 | 7 | 0 | 2 | 0 | 2 | 16 | 7 | 3 | 4 | 3 |
| Investments | 0 | 0 | 0 | 10 | 11 | 18 | 34 | 81 | 97 | 91 | 139 | 174 | 209 |
| Other Assets | 192 | 190 | 174 | 186 | 219 | 225 | 232 | 259 | 290 | 339 | 379 | 437 | 458 |
| Total Assets | 260 | 258 | 275 | 305 | 347 | 366 | 389 | 452 | 534 | 587 | 700 | 797 | 855 |
Below is a detailed analysis of the balance sheet data for Lincoln Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 20.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 20.00 Cr..
- For Reserves, as of Sep 2025, the value is 696.00 Cr.. The value appears strong and on an upward trend. It has increased from 652.00 Cr. (Mar 2025) to 696.00 Cr., marking an increase of 44.00 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 139.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 125.00 Cr. (Mar 2025) to 139.00 Cr., marking an increase of 14.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 855.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 797.00 Cr. (Mar 2025) to 855.00 Cr., marking an increase of 58.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 185.00 Cr.. The value appears strong and on an upward trend. It has increased from 182.00 Cr. (Mar 2025) to 185.00 Cr., marking an increase of 3.00 Cr..
- For CWIP, as of Sep 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4.00 Cr. (Mar 2025) to 3.00 Cr., marking a decrease of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 209.00 Cr.. The value appears strong and on an upward trend. It has increased from 174.00 Cr. (Mar 2025) to 209.00 Cr., marking an increase of 35.00 Cr..
- For Other Assets, as of Sep 2025, the value is 458.00 Cr.. The value appears strong and on an upward trend. It has increased from 437.00 Cr. (Mar 2025) to 458.00 Cr., marking an increase of 21.00 Cr..
- For Total Assets, as of Sep 2025, the value is 855.00 Cr.. The value appears strong and on an upward trend. It has increased from 797.00 Cr. (Mar 2025) to 855.00 Cr., marking an increase of 58.00 Cr..
Notably, the Reserves (696.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -48.00 | -50.00 | -37.00 | -17.00 | -8.00 | 34.00 | 61.00 | 86.00 | 94.00 | 88.00 | 99.00 | 102.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 154 | 163 | 73 | 92 | 111 | 122 | 96 | 98 | 90 | 98 | 102 | 97 |
| Inventory Days | 62 | 44 | 36 | 63 | 86 | 75 | 95 | 86 | 121 | 106 | 101 | 99 |
| Days Payable | 174 | 92 | 40 | 54 | 82 | 92 | 102 | 105 | 120 | 77 | 95 | 106 |
| Cash Conversion Cycle | 43 | 116 | 70 | 100 | 115 | 106 | 88 | 78 | 91 | 126 | 108 | 90 |
| Working Capital Days | 13 | 76 | 31 | 69 | 89 | 113 | 126 | 119 | 113 | 121 | 127 | 217 |
| ROCE % | 11% | 15% | 21% | 19% | 19% | 23% | 22% | 25% | 24% | 22% | 22% | 18% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 106 | 0.08 | 0.01 | 106 | 2025-04-22 17:25:28 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 41.11 | 46.58 | 36.40 | 34.63 | 31.11 |
| Diluted EPS (Rs.) | 41.11 | 46.58 | 36.40 | 34.63 | 31.11 |
| Cash EPS (Rs.) | 47.55 | 51.89 | 40.97 | 38.66 | 34.91 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 335.34 | 295.98 | 250.86 | 216.12 | 187.85 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 335.34 | 295.98 | 250.86 | 216.12 | 187.85 |
| Revenue From Operations / Share (Rs.) | 311.15 | 289.84 | 254.78 | 235.71 | 212.09 |
| PBDIT / Share (Rs.) | 61.89 | 67.07 | 55.76 | 52.66 | 46.42 |
| PBIT / Share (Rs.) | 55.45 | 61.76 | 51.18 | 48.62 | 42.64 |
| PBT / Share (Rs.) | 54.51 | 61.03 | 50.16 | 47.90 | 41.86 |
| Net Profit / Share (Rs.) | 41.11 | 46.58 | 36.40 | 34.63 | 31.12 |
| NP After MI And SOA / Share (Rs.) | 41.11 | 46.58 | 36.40 | 34.63 | 31.11 |
| PBDIT Margin (%) | 19.89 | 23.13 | 21.88 | 22.34 | 21.88 |
| PBIT Margin (%) | 17.82 | 21.30 | 20.08 | 20.62 | 20.10 |
| PBT Margin (%) | 17.51 | 21.05 | 19.68 | 20.32 | 19.73 |
| Net Profit Margin (%) | 13.21 | 16.07 | 14.28 | 14.69 | 14.67 |
| NP After MI And SOA Margin (%) | 13.21 | 16.07 | 14.28 | 14.69 | 14.66 |
| Return on Networth / Equity (%) | 12.25 | 15.73 | 14.50 | 16.02 | 16.58 |
| Return on Capital Employeed (%) | 16.07 | 20.34 | 19.89 | 21.94 | 22.10 |
| Return On Assets (%) | 10.33 | 13.32 | 12.41 | 12.97 | 13.54 |
| Asset Turnover Ratio (%) | 0.83 | 0.90 | 0.90 | 0.95 | 0.99 |
| Current Ratio (X) | 4.71 | 4.84 | 5.08 | 3.90 | 4.17 |
| Quick Ratio (X) | 3.97 | 4.00 | 4.11 | 3.10 | 3.53 |
| Inventory Turnover Ratio (X) | 8.00 | 7.89 | 2.48 | 2.66 | 2.18 |
| Dividend Payout Ratio (NP) (%) | 4.37 | 3.22 | 4.12 | 4.32 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 3.78 | 2.89 | 3.66 | 3.87 | 0.00 |
| Earning Retention Ratio (%) | 95.63 | 96.78 | 95.88 | 95.68 | 0.00 |
| Cash Earning Retention Ratio (%) | 96.22 | 97.11 | 96.34 | 96.13 | 0.00 |
| Interest Coverage Ratio (X) | 65.84 | 91.70 | 55.01 | 72.68 | 59.44 |
| Interest Coverage Ratio (Post Tax) (X) | 44.74 | 64.69 | 36.91 | 48.79 | 40.86 |
| Enterprise Value (Cr.) | 1082.31 | 1159.77 | 646.08 | 574.49 | 436.11 |
| EV / Net Operating Revenue (X) | 1.74 | 2.00 | 1.27 | 1.22 | 1.03 |
| EV / EBITDA (X) | 8.73 | 8.63 | 5.79 | 5.45 | 4.70 |
| MarketCap / Net Operating Revenue (X) | 1.77 | 2.02 | 1.33 | 1.32 | 1.06 |
| Retention Ratios (%) | 95.62 | 96.77 | 95.87 | 95.67 | 0.00 |
| Price / BV (X) | 1.64 | 1.98 | 1.35 | 1.44 | 1.20 |
| Price / Net Operating Revenue (X) | 1.77 | 2.02 | 1.33 | 1.32 | 1.06 |
| EarningsYield | 0.07 | 0.07 | 0.10 | 0.11 | 0.13 |
After reviewing the key financial ratios for Lincoln Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 41.11. This value is within the healthy range. It has decreased from 46.58 (Mar 24) to 41.11, marking a decrease of 5.47.
- For Diluted EPS (Rs.), as of Mar 25, the value is 41.11. This value is within the healthy range. It has decreased from 46.58 (Mar 24) to 41.11, marking a decrease of 5.47.
- For Cash EPS (Rs.), as of Mar 25, the value is 47.55. This value is within the healthy range. It has decreased from 51.89 (Mar 24) to 47.55, marking a decrease of 4.34.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 335.34. It has increased from 295.98 (Mar 24) to 335.34, marking an increase of 39.36.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 335.34. It has increased from 295.98 (Mar 24) to 335.34, marking an increase of 39.36.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 311.15. It has increased from 289.84 (Mar 24) to 311.15, marking an increase of 21.31.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 61.89. This value is within the healthy range. It has decreased from 67.07 (Mar 24) to 61.89, marking a decrease of 5.18.
- For PBIT / Share (Rs.), as of Mar 25, the value is 55.45. This value is within the healthy range. It has decreased from 61.76 (Mar 24) to 55.45, marking a decrease of 6.31.
- For PBT / Share (Rs.), as of Mar 25, the value is 54.51. This value is within the healthy range. It has decreased from 61.03 (Mar 24) to 54.51, marking a decrease of 6.52.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 41.11. This value is within the healthy range. It has decreased from 46.58 (Mar 24) to 41.11, marking a decrease of 5.47.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 41.11. This value is within the healthy range. It has decreased from 46.58 (Mar 24) to 41.11, marking a decrease of 5.47.
- For PBDIT Margin (%), as of Mar 25, the value is 19.89. This value is within the healthy range. It has decreased from 23.13 (Mar 24) to 19.89, marking a decrease of 3.24.
- For PBIT Margin (%), as of Mar 25, the value is 17.82. This value is within the healthy range. It has decreased from 21.30 (Mar 24) to 17.82, marking a decrease of 3.48.
- For PBT Margin (%), as of Mar 25, the value is 17.51. This value is within the healthy range. It has decreased from 21.05 (Mar 24) to 17.51, marking a decrease of 3.54.
- For Net Profit Margin (%), as of Mar 25, the value is 13.21. This value exceeds the healthy maximum of 10. It has decreased from 16.07 (Mar 24) to 13.21, marking a decrease of 2.86.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 13.21. This value is within the healthy range. It has decreased from 16.07 (Mar 24) to 13.21, marking a decrease of 2.86.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.25. This value is below the healthy minimum of 15. It has decreased from 15.73 (Mar 24) to 12.25, marking a decrease of 3.48.
- For Return on Capital Employeed (%), as of Mar 25, the value is 16.07. This value is within the healthy range. It has decreased from 20.34 (Mar 24) to 16.07, marking a decrease of 4.27.
- For Return On Assets (%), as of Mar 25, the value is 10.33. This value is within the healthy range. It has decreased from 13.32 (Mar 24) to 10.33, marking a decrease of 2.99.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.83. It has decreased from 0.90 (Mar 24) to 0.83, marking a decrease of 0.07.
- For Current Ratio (X), as of Mar 25, the value is 4.71. This value exceeds the healthy maximum of 3. It has decreased from 4.84 (Mar 24) to 4.71, marking a decrease of 0.13.
- For Quick Ratio (X), as of Mar 25, the value is 3.97. This value exceeds the healthy maximum of 2. It has decreased from 4.00 (Mar 24) to 3.97, marking a decrease of 0.03.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.00. This value is within the healthy range. It has increased from 7.89 (Mar 24) to 8.00, marking an increase of 0.11.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 4.37. This value is below the healthy minimum of 20. It has increased from 3.22 (Mar 24) to 4.37, marking an increase of 1.15.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 3.78. This value is below the healthy minimum of 20. It has increased from 2.89 (Mar 24) to 3.78, marking an increase of 0.89.
- For Earning Retention Ratio (%), as of Mar 25, the value is 95.63. This value exceeds the healthy maximum of 70. It has decreased from 96.78 (Mar 24) to 95.63, marking a decrease of 1.15.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 96.22. This value exceeds the healthy maximum of 70. It has decreased from 97.11 (Mar 24) to 96.22, marking a decrease of 0.89.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 65.84. This value is within the healthy range. It has decreased from 91.70 (Mar 24) to 65.84, marking a decrease of 25.86.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 44.74. This value is within the healthy range. It has decreased from 64.69 (Mar 24) to 44.74, marking a decrease of 19.95.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,082.31. It has decreased from 1,159.77 (Mar 24) to 1,082.31, marking a decrease of 77.46.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.74. This value is within the healthy range. It has decreased from 2.00 (Mar 24) to 1.74, marking a decrease of 0.26.
- For EV / EBITDA (X), as of Mar 25, the value is 8.73. This value is within the healthy range. It has increased from 8.63 (Mar 24) to 8.73, marking an increase of 0.10.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.77. This value is within the healthy range. It has decreased from 2.02 (Mar 24) to 1.77, marking a decrease of 0.25.
- For Retention Ratios (%), as of Mar 25, the value is 95.62. This value exceeds the healthy maximum of 70. It has decreased from 96.77 (Mar 24) to 95.62, marking a decrease of 1.15.
- For Price / BV (X), as of Mar 25, the value is 1.64. This value is within the healthy range. It has decreased from 1.98 (Mar 24) to 1.64, marking a decrease of 0.34.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.77. This value is within the healthy range. It has decreased from 2.02 (Mar 24) to 1.77, marking a decrease of 0.25.
- For EarningsYield, as of Mar 25, the value is 0.07. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.07.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lincoln Pharmaceuticals Ltd:
- Net Profit Margin: 13.21%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 16.07% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.25% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 44.74
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.97
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 12.4 (Industry average Stock P/E: 54.07)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 13.21%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Lincoln House, Ahmedabad Gujarat 380060 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Kishor M Shah | Non Executive Chairman |
| Mr. Mahendra G Patel | Managing Director |
| Mr. Hashmukh I Patel | Whole Time Director |
| Mr. Munjal M Patel | Whole Time Director |
| Mr. Ashish R Patel | Whole Time Director |
| Mr. Rajnikant G Patel | Non Executive Director |
| Mr. Nareshkumar Suthar | Independent Director |
| Mr. Saurin J Parikh | Independent Director |
| Ms. Seema Mehta | Independent Director |
FAQ
What is the intrinsic value of Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd's intrinsic value (as of 02 January 2026) is ₹454.94 which is 8.46% lower the current market price of ₹497.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹996 Cr. market cap, FY2025-2026 high/low of ₹872/464, reserves of ₹696 Cr, and liabilities of ₹855 Cr.
What is the Market Cap of Lincoln Pharmaceuticals Ltd?
The Market Cap of Lincoln Pharmaceuticals Ltd is 996 Cr..
What is the current Stock Price of Lincoln Pharmaceuticals Ltd as on 02 January 2026?
The current stock price of Lincoln Pharmaceuticals Ltd as on 02 January 2026 is ₹497.
What is the High / Low of Lincoln Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Lincoln Pharmaceuticals Ltd stocks is ₹872/464.
What is the Stock P/E of Lincoln Pharmaceuticals Ltd?
The Stock P/E of Lincoln Pharmaceuticals Ltd is 12.4.
What is the Book Value of Lincoln Pharmaceuticals Ltd?
The Book Value of Lincoln Pharmaceuticals Ltd is 357.
What is the Dividend Yield of Lincoln Pharmaceuticals Ltd?
The Dividend Yield of Lincoln Pharmaceuticals Ltd is 0.36 %.
What is the ROCE of Lincoln Pharmaceuticals Ltd?
The ROCE of Lincoln Pharmaceuticals Ltd is 17.3 %.
What is the ROE of Lincoln Pharmaceuticals Ltd?
The ROE of Lincoln Pharmaceuticals Ltd is 12.8 %.
What is the Face Value of Lincoln Pharmaceuticals Ltd?
The Face Value of Lincoln Pharmaceuticals Ltd is 10.0.